Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
AlloVir logo — A global leader in allogeneic, off-the-shelf, multi-virus sp...

AlloVir

A global leader in allogeneic, off-the-shelf, multi-virus specific T- cell immunotherapies

Founded 2013 United States Waltham, United States 32 employees Post-IPO Equity Total: $360.59M Biotechnology, Pharmaceutical

General Information

Company Name AlloVir
Founded Year 2013
Location United States Waltham, United States
Employees 32
Industries Biotechnology, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with AlloVir. To contact AlloVir, visit allovir.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AlloVir compare?

A PDF of AlloVir and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AlloVir soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AlloVir

AlloVir is a biotechnology startup founded in 2013 and headquartered in the United States. The company is a pioneer in the development of allogeneic, off-the-shelf, multi-virus specific T-cell immunotherapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. AlloVir's technology platforms aim to provide commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viral pathogens for immunocompromised patients under viral attack. Their innovative technology and manufacturing process enable the potential treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. Furthermore, the company is actively advancing multiple mid- and late-stage clinical trials across its product portfolio. Their most recent investment of $75.00M in post-IPO equity was made on 21 June 2023.

Business keywords: Cell Therapy, Immunotherapy, Allogeneic, T-cell therapy, Viral diseases, Clinical Trials, Immune System, Life-threatening diseases, Infectious Diseases, Viral Pathogens, Biopharmaceuticals, Healthcare Innovation, Patient Care, Medical Research

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $75.00M -
21 Jun 2023
Post IPO Equity $126.60M 8
Invus Redmile Group EcoR1 Capital
Invus, Redmile Group +6
27 Jul 2022
Series B $120.00M 2
Fidelity
Fidelity, Leerink Partners
23 May 2019
Venture Round $30.00M -
17 Sep 2018
Grant $8.99M -
18 Aug 2017

AlloVir Alternatives & Competitors

View All Alternatives
AlloVir vs
Medeor Therapeutics, Inc.
Medeor Therapeutics, Inc. United States

Redefining Transplant

Grant
5 employees
Biotechnology, Health and Wellness
Compare AlloVir vs Medeor Therapeutics, Inc.
AlloVir vs
American Gene Technologies® International Inc.
American Gene Technologies® International Inc. United States

Our mission is to leverage the power of gene and cell therapy to reduce human suffering from serious...

Series F
26 employees
Biotechnology, Health Care
Compare AlloVir vs American Gene Technologies® International Inc.
AlloVir vs
Memgen, Inc.
Memgen, Inc. United States

Memgen's Vision: Develop Life-Saving Cancer Immunotherapies

Venture round
7 employees
Biotechnology, Health Care
View all alternatives

FAQ About AlloVir

A global leader in allogeneic, off-the-shelf, multi-virus specific T- cell immunotherapies
AlloVir was founded in 2013.
AlloVir is headquartered in Waltham, United States.
AlloVir operates in Biotechnology and Pharmaceutical. Its work centres on Cell Therapy, Immunotherapy, Allogeneic and T-cell therapy.
AlloVir has approximately 32 employees.
AlloVir has completed 5 funding rounds, raising a total of $360.59M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to AlloVir include Medeor Therapeutics, Inc., American Gene Technologies® International Inc., Memgen, Inc., VaxCell Biotherapeutics Co., Ltd., Juventas Cell Therapy Corp.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AlloVir and Medeor Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AlloVir, https://bouncewatch.com/company/allovir, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes